Unlock instant, AI-driven research and patent intelligence for your innovation.

Drug microparticles

a technology of microparticles and drugs, applied in the field of microparticles of drugs, can solve the problems of poor oral bioavailability of many important drugs, limited prodrug approach, and different approaches to achieve the effect of improving oral bioavailability

Inactive Publication Date: 2006-06-29
LERNER E ITZHAK +4
View PDF19 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"The present invention is about a drug delivery system that includes a carrier particle, such as a sugar or starch particle, that has microparticles of a drug deposited on it. The drug is dissolved in a sublimable carrier and then the carrier is removed, leaving behind the microparticles of the drug. This system can be used to deliver drugs that are difficult to dissolve in water to mammals, including humans. The invention also includes a method for making the microparticles and pharmaceutical compositions containing them. The technical effect of this invention is a more effective delivery of drugs that are difficult to dissolve in water."

Problems solved by technology

Many important drugs have poor oral bioavailability because they are poorly soluble in water.
Although some approaches have been used, with limited commercial success, each approach has its own drawbacks and limitations.
The prodrug approach is limited to those molecules that have functionality amenable to facile removal in the body to form the drug.
Furthermore, the prodrug would likely be considered a new chemical entity and require separate approval from regulatory agencies, adding considerable time and cost to bringing the product to market.
Size reduction is, in principal, generally applicable for improving bioavailability, but achieving size reduction by, for example, high energy milling, requires special equipment and is not always applicable.
Spray drying also requires solvents and generally produces particles that are too large.
Lyophilization is usually limited to materials that are soluble in water in any event, although there have been some efforts at using organic solvents.
Lyophilization is usually a very slow, energy intensive process and usually requires high vacuum equipment.
Furthermore, there is a tendency for the crystals formed to aggregate in the free state, undoing the job that the freeze drying did.
Amorphous or nanoparticulate materials tend to show poor bulk flow properties as powders, requiring formulation work to be able to fill them into capsules.
While these problems are not insurmountable, they add further limitations in the usefulness of the system.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

Solubility of Selected Drugs in Menthol

[0046] The following general procedure was repeated with several drugs with menthol carrier.

[0047] Menthol (10 grams) was melted on a stirring hot plate with magnetic stirring, then heated to the desired temperature indicated in Table 1. The desired drug was added in small increments (0.1 grams) and stirred to obtain a clear solution. The desired drug was added in increments until no more drug dissolved in the menthol. The weight of material added to the menthol melt that still gave a clear solution was taken as the solubility of the active drug at the indicated temperature. The results are given in Table 1.

TABLE 1Solubility of selected active drug substances in mentholSolubilityActive drug substancetemperature (° C.)(% w / w)Azithromycin6340.0Cyclosporin5539.2Diazepam435.7Fenofibrate6037.5Itraconazole611.0Oxybutynin609.1Risperidone708.3Salicylic acid4316.0Simvastatin6330.0

example 2

Improvement of the Dissolution of Fenofibrate by “Menthol Micronization

[0048] Menthol (50 grams) was heated in a jacketed reactor to 60° C. After melting, the melt was stirred at 100 rpm. Fenofibrate (25 grams) was added and the mixture stirred at 100 rpm and 60° C. until full dissolution was achieved. Microcrystalline cellulose (Avicel ph 102, 55 grams) was added to the melt and the mixture was stirred for 30 minutes. The heat source was then removed and the mass allowed to cool to room temperature with the stirring continued at 100 rpm for a further 30 minutes.

[0049] The obtained mass was milled through a 6.35 mm screen in a Quadro Comil mill at 1300 rpm. The milled product was allowed to cool to 25° C. and milled again through 1.4 mm screen to obtain a powder in which the fenofibrate is dissolved in menthol and coated on the microcrystalline cellulose.

[0050] The powder was transferred to a fluid bed dryer (Aeromatic model STREA1) where the menthol was removed by drying for thr...

example 3

Improvement of the Dissolution of Oxybutynin Chloride by “Menthol Micronization

[0052] Menthol (80 grams) was melted and oxybutynin chloride (8 grams) and microcrystalline cellulose (89.5 grams) were added and treated as in Example 2 to give a powder of “micronized” oxybutynin chloride on microcrystalline cellulose.

[0053] The dissolution of oxybutynin chloride from this powder ( a sample of powder containing 100 mg of the active drug) was tested in a USP apparatus II dissolution tester in 100 ml of 50 mM phosphate buffer pH=6.8 at 37° C. and 50 rpm. The oxybutynin content of the dissolution sample was measured by spectrophotometer at 225 nm. The results are given in Table 3. The dissolution reached 79.2% at three hours. An equivalent simple combination of the oxybutynin chloride raw material with microcrystalline cellulose that was not treated with the “menthol micronization” method gave only 22.1% dissolution in three hours.

TABLE 3Dissolution of menthol treated oxybutynintime (m...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
weight-%aaaaaaaaaa
sizeaaaaaaaaaa
Login to View More

Abstract

Provided are microparticles of active pharmaceutical ingredients, drug delivery vehicles comprising same, and methods for making them.

Description

RELATED APPLICATONS [0001] The present Application is a Continuation of U.S. Non-Provisional Application Ser. No. 10 / 400,100, filed on Mar. 25, 2003, and claims the benefit of the Mar. 26, 2002 filing date of U.S. Provisional Patent Application No. 60 / 367,957.FIELD OF THE INVENTION [0002] The present invention relates to microparticles of drugs, especially drugs that are poorly soluble in water, and to methods for making them. BACKGROUND OF THE INVENTION [0003] Many important drugs have poor oral bioavailability because they are poorly soluble in water. Many approaches have been suggested to overcome this problem. Although some approaches have been used, with limited commercial success, each approach has its own drawbacks and limitations. [0004] In one approach, a water-soluble prodrug of a poorly water-soluble drug is made [1-4]. The prodrug approach is limited to those molecules that have functionality amenable to facile removal in the body to form the drug. Not all poorly water-s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/519A61K9/14A61K9/16A61K31/192A61K31/216A61K31/277A61K31/366A61K31/496A61K31/5513A61K31/60A61K31/7052A61K38/00A61K47/06A61K47/08A61K47/10A61K47/12A61K47/16A61K47/20A61K47/22A61K47/26A61K47/36A61K47/38
CPCA61K9/167A61K9/1676A61K31/519B01J13/02B01J13/125A61K9/1682A61K9/1694A61P35/00A61K9/14A61K47/06
Inventor LERNER, E. ITZHAKROSENBERGER, VEREDFLASHNER-BARAK, MOSHEDRABKIN, ANNAMOLDAVSKI, NAOMI
Owner LERNER E ITZHAK